The double-blind, randomized, placebo-controlled trial included 1256 participants with impaired glucose tolerance. Participants were randomly assigned to receive eldecalcitol or placebo for 3 years. No overall difference was found between patients taking eldecalcitol and the placebo group in the rates of regression to normoglycemia or incidence of type 2 diabetes. However, after adjustment for prespecified covariables, eldecalcitol was effective in preventing the development of type 2 diabetes among those with the lowest divisions of homeostatic model assessment (HOMA), HOMA-insulin resistance, and fasting immunoreactive insulin. The researchers concluded that vitamin D supplementation benefitted insufficient basal insulin secretion. Differences in rates and types of adverse events between the two groups were insignificant.
Learn more about vitamin D supplementation.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori. Rapid Review Quiz: Vitamin D - Medscape - Sep 06, 2022.